Bellus Health
Bellus Health is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for rare diseases, with a particular focus on conditions affecting the kidneys. Its lead drug candidate, KIACTA™, is designed for the treatment of AA amyloidosis, a rare condition that can result in severe renal dysfunction. Following the successful completion of a Phase 3 study, the company is collaborating with Auven Therapeutics to advance KIACTA™, which is also being explored for treating sarcoidosis, an inflammatory disease affecting the lungs. Additionally, Bellus Health is developing Shigamab™, an antibody treatment for Hemolytic Uremic Syndrome, a serious condition linked to Shiga toxin-producing E. coli, which poses significant health risks, especially for children. The company's research pipeline also includes efforts to address AL amyloidosis, another rare disease characterized by the accumulation of amyloid proteins in the body. Bellus Health aims to meet the high unmet medical needs of patients suffering from these conditions through its focused therapeutic developments.
Top Regions
Top Stages
2 past transactions
Thallion Pharmaceuticals
Acquisition in 2013
Thallion Pharmaceuticals Inc. is a biotechnology company specializing in the development of pharmaceutical products targeting infectious diseases and oncology. Its primary product candidate, Shigamabs, is a dual antibody treatment currently undergoing Phase II clinical trials for Shigatoxin-producing E. coli (STEC) infections. The company has successfully completed multiple Phase I trials demonstrating the safety and tolerability of Shigamabs. Additionally, Thallion has a proprietary genomics-based discovery platform, DECIPHER, which is designed to identify novel secondary metabolites from non-pathogenic microorganisms. Another significant clinical program is TLN-4601, a novel small molecule aimed at treating various cancer indications, including both solid and liquid tumors. Founded in 1998 and headquartered in Dorval, Canada, Thallion operates as a subsidiary of Taro Pharmaceuticals Inc.
Innodia
Acquisition in 2008
Innodia is a privately held biopharmaceutical company focused on the development and marketing of innovative drugs aimed at treating type 2 diabetes and related conditions. The company is dedicated to advancing healthcare solutions through the introduction of novel pharmaceuticals that address unmet medical needs. By leveraging cutting-edge research and development, Innodia seeks to improve the quality of life for patients managing diabetes, demonstrating a commitment to enhancing therapeutic options in the biopharmaceutical landscape.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.